UK Aid Reductions Undermine HIV Prevention Efforts in Africa
As a woman living with HIV, I am acutely aware of the critical importance of accessible prevention and treatment services, and the profound devastation that arises when they are unavailable. I have personally experienced the fear and anxiety of struggling to access clinics and medications, as well as the hope brought by scientific advancements and the despair when these breakthroughs remain out of reach for the most vulnerable. This personal perspective fuels my deep concern over the UK's decision to slash £900 million in bilateral aid to Africa, a move that I believe represents a significant betrayal of women and girls in sub-Saharan Africa.
Immediate Impacts of Funding Cuts on HIV Services
Prior to these recent announcements, cuts from donor nations were already taking a severe toll. Reports from friends and family across South Africa indicate that individuals are facing difficulties in obtaining HIV medicines, medical appointments are being cancelled, and marginalised communities are bearing the brunt of these reductions. Concurrently, HIV testing and prevention services are being scaled back, with community testing sites closing, outreach efforts faltering, and people losing access to essential tools that prevent new infections. As testing rates decline, more individuals remain unaware of their HIV status, infections go undetected, and transmission risks escalate. These are not merely abstract policy decisions; they are actively dismantling decades of hard-won progress in HIV treatment, testing, and prevention, placing lives at immediate risk, particularly among those with limited alternatives.
The Paradox of Medical Advancement Amid Financial Withdrawal
It presents a confusing paradox: while financial aid is being drastically reduced, we are simultaneously witnessing a transformative medical breakthrough. Lenacapavir, a long-acting injectable HIV prevention drug administered only twice a year, represents the closest we have come to developing an HIV vaccine. This discreet and sustained protection eliminates the need for daily pills and associated stigma, while also reducing the mental burden for high-risk groups, such as women and girls. Groundbreaking trials in South Africa and Uganda showed no new HIV infections among women who received lenacapavir, with African women and girls playing a central role in the success of these studies. This underscores the effectiveness of inclusive, locally grounded science.
Disproportionate Burden and Risk of Exclusion
In sub-Saharan Africa, women and girls account for approximately two-thirds of all new HIV infections, bearing a disproportionate burden due to compounding factors like economic insecurity, gender-based discrimination, and violence. These issues not only increase their risk of acquiring HIV but also exacerbate the negative impacts. Despite their pivotal involvement in the development and success of lenacapavir, there is a real danger that these women and girls could be excluded from benefiting from the drug. A scientific breakthrough alone is insufficient; confining lenacapavir to laboratories or high-income markets, out of reach for those who need it most, would constitute a failure of its very purpose and a profound betrayal of justice and equity.
The Role of Political Choices and UK Investment
Political decisions are crucial in this context. UK Official Development Assistance cuts threaten to jeopardise a historic opportunity to prevent HIV acquisition among women and girls across sub-Saharan Africa. While lenacapavir has the potential to save countless lives, its impact will only be realised if funding and partnerships supporting its delivery are maintained. The UK has previously supported Unitaid, a multilateral organisation that has made lenacapavir more accessible, affordable, and scalable. UK investment has aided Unitaid's efforts with the South African government to produce generic lenacapavir locally, which is essential for sustainability. Producing medicines closer to the communities that need them ensures a reliable supply, reduces dependence on distant markets, lowers costs, and builds resilient health systems. When combined with robust delivery systems and stigma-free services, this approach not only prevents HIV but also strengthens health infrastructure, fosters local expertise, and positions countries like South Africa as regional hubs for life-saving innovation.
A Call for Continued Leadership and Investment
The UK now faces a critical choice. After years of championing global health and supporting scientific innovation, it risks retreating at a pivotal moment. Decisions made by the UK will determine whether this breakthrough reaches the women and girls who need it most. Science has delivered, and African women have made it possible; now, political leadership must ensure that women benefit. Supporting continued UK investment in Unitaid and its partnerships is not merely an act of generosity but a smart investment in global health, regional resilience, and the lives of millions. It is a choice between action and inaction, between leaving innovation on the shelf and putting it into the arms of those who need it. History will remember this moment not for the breakthrough itself, but for whether we allowed it to reach those it was designed to protect. The UK can ensure that lenacapavir fulfills its promise, or it can step back and risk countless lives being lost while science waits.
